Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors-Reference-Cited by-同舟云学术

Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors

Published:2020-09-01 Issue:9 Volume:30 Page:1288-1296
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Cabanillas Maria E.¹,Dadu Ramona¹,Iyer Pryianka¹,Wanland Kacey B.¹,Busaidy Naifa L.¹,Ying Anita¹,Gule-Monroe Maria²,Wang Jennifer R.³,Zafereo Mark³,Hofmann Marie-Claude¹

Affiliation:

1. Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

2. Department of Diagnostic Radiology, and The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

3. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2019.0514

Reference66 articles.

1. BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study

2. High Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid Carcinoma

3. DoesBRAFV600E Mutation Predict Aggressive Features in Papillary Thyroid Cancer? Results From Four Endocrine Surgery Centers

4. TheBRAFV600E Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study

5. Papillary Thyroid Carcinomas with Cervical Lymph Node Metastases Can Be Stratified into Clinically Relevant Prognostic Categories Using Oncogenic BRAF, the Number of Nodal Metastases, and Extra-Nodal Extension

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of the BRAFV600E Mutation in Circulating Free Nucleic Acids as a Biomarker of Thyroid Cancer: A Review;Journal of Clinical Medicine;2024-09-12

2. POU5F1B is responsible for the acquired resistance to dabrafenib in papillary thyroid cancer cells with the BRAF V600E mutation;Endocrine;2024-08-13

3. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer;JAMA Oncology;2024-07-11

4. Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer;Head and Neck Tumors (HNT);2024-06-28

5. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy;Frontiers in Immunology;2024-05-29